Aya Fukuma Ozaki

Picture of Aya Fukuma Ozaki
Assistant Professor of Clinical Pharmacy
School of Pharmacy & Pharmaceutical Sciences
B.S., School of Pharmaceutical Sciences, Toho University, Japan, Pharmacology
Pharm.D., College of Pharmacy, Western University of Health Sciences
Phone: (949)824-3942
Email: afozaki@uci.edu
University of California, Irvine
Berk Hall, 106D
Mail Code: 3958
Irvine, CA 92697
Research Interests
Cardiovascular diseases, medication utilization, pharmacogenomics, health disparities, evidence-based medicine
Publications
Ozaki AF, Sayer M, Hamano H, et al. Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy. Cardiooncology. 2025;11(1):26. Published 2025 Mar 5. doi:10.1186/s40959-025-00300-1
Khorassani F, Entsuah-Boateng N, Sayer M, Ozaki AF. Racial Disparities in Mood Stabilizer Prescribing in Mania in Nonpsychotic, Hospitalized Patients With Bipolar I Disorder. J Clin Psychiatry. 2025;86(1):24m15524. Published 2025 Feb 3. doi:10.4088/JCP.24m15524
Agapito I, Hoang T, Sayer M, Naqvi A, Patel PM, Ozaki AF. Sex-based disparities with cost-related medication adherence issues in patients with hypertension, ischemic heart disease, and heart failure. J Am Med Inform Assoc. Published online July 31, 2024. doi:10.1093/jamia/ocae203
Enomoto K, Hashi H, Jackevicius CA, Nakagawa S, Ozaki AF. Perceptions, knowledge, and perceived barriers to practicing evidence-based medicine among pharmacists in Japanese community hospitals: A cross-sectional multicenter survey. J Am Coll Clin Pharm. 2024; 7(5): 471-478. doi:10.1002/jac5.1950
Moon J, Ozaki AF, Chong A, Sud M, Fang J, Austin PC, Ko DT, Jackevicius CA. Comparing Measures of Adherence and Persistence to P2Y12 Inhibitors in Acute Coronary Syndromes. Am J Cardiol. 2024;226:134-136. doi:10.1016/j.amjcard.2024.04.047
Oka Y, Matsumoto J, Takeda T, Iwata N, Niimura T, Ozaki AF, Bekku K, Hamano H, Araki M, Ishizawa K, Zamami Y, Ariyoshi N. Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study. Int J Clin Pharm. 2024;46(3):745-750. doi:10.1007/s11096-024-01713-1
Yusuf R, Quan Ng D, Sepassi A, Ozaki AF, Griffin S, Entsuah-Boateng N. Prescription and Non-Prescription Drug Use during the Covid-19 Pandemic among Racial-Ethnic Identities. Rep GlobHealth Res 2024;7: 195. https://doi.org/10.29011/2690-9480.100195.
Takeda T, Sugimoto S, Matsumoto J, Iwata N, Nakamoto A, Ozaki AF, Hamano H, Ariyoshi N, Zamami Y. A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases. Int J Clin Pharm. 2024;46(2):536-541. doi:10.1007/s11096-023-01687-6
Moon J, Ozaki AF, Chong A, Sud M, Fang J, Austin PC, Ko DT, Jackevicius CA. Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes. Pharmacoepidemiol Drug Saf. 2024;33(1):e5704. doi:10.1002/pds.5704
Tran H, Nguyen J, Ozaki AF. Evidence-based practice review of the SECURE Trial. J Contemp Pharm Practice. 2023;70:27-31
Mitsuboshi S, Hamano H, Niimura T, Ozaki AF, Patel MP, Lin TJ, Tanaka Y, Kimura I, Iwata N, Shiromizu S, Chuma M, Koyama T, Yamanishi Y, Kanda Y, Ishizawa K, Zamani Y. Association between immune checkpoint inhibitor-induced myocarditis and concomitant use of thiazide diuretics. Int J Cancer. 2023;10.1002/ijc.34616. doi:10.1002/ijc.34616
Ozaki AF, Ko DT, Chong A, Fang J, Atzema CL, Austin PC, Stukel T, Tu K, Udell JA, Naimark D, Booth GL, Jackevicius CJ. Prescribing patterns and factors associated with sodium-glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease. CMAJ Open. 2023;11(3):E494-E503.
12 Urano K, Hatano N, Ozeki K, Komoda M, Kawahara M, Ozaki AF. How to promote practical EBM education - The learning cycle in university and clinical practice. Japan Society of Pharmaceutical Education. (Accepted) Description: I contributed to designing the study, drafting and critical revision of the manuscript.
11 Ozaki AF, Jackevicius CA, Chong A, Sud M, Fang J, Austin PC, Ko DT. Hospital-level variation in ticagrelor use in patients with acute coronary syndrome. J Am Heart Assoc. 2022;11(13):e024835. Description: I led the research team, designed the study, drafted and finalized the manuscript.
10 Ozaki AF, Cadiz C, Hurley-Kim K, Wisseh C, Knox E, Lee JY, Wong A, Patel SG, Chan A. worldwide characteristics and trends of pharmacist interventions contributed to minimize health disparities. J Am Coll Clin Pharm. 2022;5(8):853-64 Description: As a primary and corresponding author, I led the team to develop the study, collect and analyze data, and write the manuscript.
9 Hurley-Kim K, Unonu J, Wisseh C, Cadiz C, Knox E, Ozaki AF, Chan A. Health disparities in pharmacy practice within the community: Let's brainstorm for solutions. Front Public Health. 2022;10:847696. Description: I contributed to designing the study, drafting and critical revision of the manuscript.
8 Ozaki AF, Krumholz HM, Mody FV, et al. Prior authorization, copayments, and utilization of sacubitril/valsartan in medicare and commercial plans in patients with heart failure with reduced ejection fraction [published online ahead of print, 2021 Sep 1]. Circ Cardiovasc Qual Outcomes 2021;CIRCOUTCOMES120007665. Description: I led the research team, designed the study, analyzed, drafted and finalized the manuscript.
7 Ozaki AF, Krumholz HM, Mody FV, Jackevicius CA. National trends in the use of sacubitril/valsartan. J Card Fail 2021;27:839-47. Description: I led the research team, designed the study, analyzed, drafted and finalized the manuscript.
6 Hamaguchi S, Kariya M, Ozaki AF, Namekata I, Tanaka H. Contribution of ATP-mediated positive feedback to sympathetic nerve-induced positive inotropy in guinea pig ventricular myocardium. Biol Pharm Bull 2021;44:458-60. Description: I contributed to designing the study and critical revision of the manuscript
5 Ozaki AF, Choi AS, Le QT, Ko DT, Han JK, Park SS, Jackevicius CA. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2020;13:e005969. doi:10.1161/CIRCOUTCOMES.119.005969 Description: I led the research team, designed the study, analyzed, drafted and finalized the manuscript.
4 Jackevicius CA, Krumholz HM, Chong A, Koh M, Ozaki AF, Austin PC, Udell JA, Ko DT. Population impact of generic valsartan recall. Circulation. 2020;141:411-3. doi:10.1161/CIRCULATIONAHA.119.044494 Description: I contributed to designing the study, and critical revision of the manuscript.
3 Ny P, Ozaki AF, Pallares J, Nieberg P, Wong-Beringer A. Antimicrobial stewardship opportunities in patients with bacteremia not identified by BioFire FilmArrary. J Clin Microbiol. 2019 Apr;57(5). Pii: e01941-18. doi: 10.1128/JCM.01941-18 Description: I contributed to designing the study and analyzing data.
2 Ozaki AF, Jackevicius CA. Evidence-based practice review of the ASCEND Trial. J Contemp Pharm Practice. 2019;66:48-52 Description: I designed the study, analyzed, drafted and revised the manuscript.
1 Ozaki AF, Nakagawa S, Jackevicius CA. Cross-cultural comparison of pharmacy students’ attitudes, knowledge, practice, and barriers regarding evidence-based medicine. Am J Pharm Educ. 2017; Published online ahead of print Dec 12, 2017. doi/pdf/10.5688/ajpe6710 Description: I led the research team, designed the study, analyzed, drafted and finalized the manuscript.
Other Experience
Fellow in Cardiovascular Outcomes Research
Western University of Health Sciences, Practice Site: Veterans Affair Greater Los Angeles 2018—2021
Last updated
03/19/2025